Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sabroxy™ shows promise for mild memory loss in small trial

NCT ID NCT07189754

Symptom relief Sponsor: SF Research Institute, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether Sabroxy™, a supplement made from the bark of the Oroxylum indicum tree, can improve memory and thinking in adults aged 60 to 85 with mild cognitive concerns. About 70 participants took either Sabroxy™ or a placebo twice daily for 12 weeks. Researchers measured changes in cognitive tests and blood levels of a brain-health protein called BDNF. The goal is to see if this natural extract can safely support brain function in aging adults.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sabroxy™ (Oroxylum indicum extract)
What this could lead to
If it works, this could point toward a natural supplement to help older adults with mild memory problems think more clearly.
What could go wrong
This is a small, early-stage study with only 70 participants. The results may not apply to everyone, and the supplement might not work better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

70 people

The number who actually took part.

Started

Nov 2020

Finished

Feb 2021

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy adults (male and female), 60 to 85 years old Residing in independent living accommodation Subjective reports of memory or cognitive impairment (answering "yes" to at least one of the following): Do you feel your memory and thinking is getting worse? Do you feel your memory and thinking has become worse over the past 2-3 years? Are you concerned about your decline in memory and thinking? Modified Montreal Cognitive Assessment (MoCA) score consistent with mild impairment Non-smoker Body Mass Index (BMI) between 18 and 35 kg/m² No plans to commence new treatments over the study period Understands and is willing to comply with study procedures Provides signed and dated informed consent Exclusion Criteria: * Diagnosis of dementia (per NIA/AA criteria) Uncontrolled hypertension, cardiovascular disease (MI, angina, CHF), bleeding disorders, type I diabetes, glaucoma, renal/hepatic disease, pulmonary or significant GI disease, gallbladder/biliary disease, or neurodegenerative/neurological disease Significant psychiatric disorder (schizophrenia, bipolar disorder, OCD, personality disorder) History of stroke, seizures, or head injury with loss of consciousness Moderate-to-severe depression or anxiety (per Depression, Anxiety, Stress Scale) Regular use of anticoagulants, anticholinergics, acetylcholinesterase inhibitors, or steroids Medication change in past 3 months or expected changes during study Use of vitamins or herbal supplements that may affect cognition Current or recent (12 months) illicit drug abuse Alcohol intake \>14 drinks/week Significant surgery in the last year

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive dysfunction, cognitive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cognitive disorder Cognitive Dysfunction Memory Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive dysfunction, cognitive disorder Memory problems Mild cognitive impairment (MCI)

Contacts and locations

Locations

  • San Francisco Research Institute

    San Francisco, California, 94132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.